S&P 500   4,000.70 (+0.52%)
DOW   31,722.10 (+0.45%)
QQQ   299.77 (+0.27%)
AAPL   155.44 (-0.33%)
MSFT   258.66 (+0.22%)
META   161.39 (+0.62%)
GOOGL   109.13 (-0.29%)
AMZN   129.65 (+0.13%)
TSLA   287.00 (+1.16%)
NVDA   138.36 (+0.89%)
NIO   17.48 (+0.00%)
BABA   90.00 (-0.66%)
AMD   82.34 (+3.43%)
T   16.88 (+0.06%)
MU   54.87 (-0.24%)
CGC   3.40 (-0.29%)
F   15.22 (-1.36%)
GE   73.77 (+0.26%)
DIS   112.55 (-0.12%)
AMC   8.60 (+2.50%)
PYPL   95.65 (+0.72%)
PFE   46.59 (+1.00%)
NFLX   227.07 (-0.83%)
S&P 500   4,000.70 (+0.52%)
DOW   31,722.10 (+0.45%)
QQQ   299.77 (+0.27%)
AAPL   155.44 (-0.33%)
MSFT   258.66 (+0.22%)
META   161.39 (+0.62%)
GOOGL   109.13 (-0.29%)
AMZN   129.65 (+0.13%)
TSLA   287.00 (+1.16%)
NVDA   138.36 (+0.89%)
NIO   17.48 (+0.00%)
BABA   90.00 (-0.66%)
AMD   82.34 (+3.43%)
T   16.88 (+0.06%)
MU   54.87 (-0.24%)
CGC   3.40 (-0.29%)
F   15.22 (-1.36%)
GE   73.77 (+0.26%)
DIS   112.55 (-0.12%)
AMC   8.60 (+2.50%)
PYPL   95.65 (+0.72%)
PFE   46.59 (+1.00%)
NFLX   227.07 (-0.83%)
S&P 500   4,000.70 (+0.52%)
DOW   31,722.10 (+0.45%)
QQQ   299.77 (+0.27%)
AAPL   155.44 (-0.33%)
MSFT   258.66 (+0.22%)
META   161.39 (+0.62%)
GOOGL   109.13 (-0.29%)
AMZN   129.65 (+0.13%)
TSLA   287.00 (+1.16%)
NVDA   138.36 (+0.89%)
NIO   17.48 (+0.00%)
BABA   90.00 (-0.66%)
AMD   82.34 (+3.43%)
T   16.88 (+0.06%)
MU   54.87 (-0.24%)
CGC   3.40 (-0.29%)
F   15.22 (-1.36%)
GE   73.77 (+0.26%)
DIS   112.55 (-0.12%)
AMC   8.60 (+2.50%)
PYPL   95.65 (+0.72%)
PFE   46.59 (+1.00%)
NFLX   227.07 (-0.83%)
S&P 500   4,000.70 (+0.52%)
DOW   31,722.10 (+0.45%)
QQQ   299.77 (+0.27%)
AAPL   155.44 (-0.33%)
MSFT   258.66 (+0.22%)
META   161.39 (+0.62%)
GOOGL   109.13 (-0.29%)
AMZN   129.65 (+0.13%)
TSLA   287.00 (+1.16%)
NVDA   138.36 (+0.89%)
NIO   17.48 (+0.00%)
BABA   90.00 (-0.66%)
AMD   82.34 (+3.43%)
T   16.88 (+0.06%)
MU   54.87 (-0.24%)
CGC   3.40 (-0.29%)
F   15.22 (-1.36%)
GE   73.77 (+0.26%)
DIS   112.55 (-0.12%)
AMC   8.60 (+2.50%)
PYPL   95.65 (+0.72%)
PFE   46.59 (+1.00%)
NFLX   227.07 (-0.83%)
NASDAQ:CERT

Certara - CERT Stock Forecast, Price & News

$16.39
+0.73 (+4.66%)
(As of 09/8/2022 10:47 AM ET)
Add
Compare
Today's Range
$15.71
$16.58
50-Day Range
$15.10
$24.13
52-Week Range
$14.94
$45.48
Volume
5,621 shs
Average Volume
1.24 million shs
Market Capitalization
$2.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.57

Certara MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
66.8% Upside
$26.13 Price Target
Short Interest
Healthy
2.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.73
Upright™ Environmental Score
News Sentiment
0.31mentions of Certara in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$107.90 M Sold Last Quarter
Proj. Earnings Growth
53.57%
From $0.28 to $0.43 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.29 out of 5 stars

Medical Sector

10th out of 1,091 stocks

Prepackaged Software Industry

6th out of 223 stocks

CERT stock logo

About Certara (NASDAQ:CERT) Stock

Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

Receive CERT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Certara and its competitors with MarketBeat's FREE daily newsletter.

CERT Stock News Headlines

Certara, Inc. (NASDAQ: CERT)
Credit Suisse Group Initiates Coverage on Certara (NASDAQ:CERT)
Certara, Inc. (NASDAQ:CERT) Insider Sells $177,100.00 in Stock
Barclays Cuts Certara (NASDAQ:CERT) Price Target to $21.00
Certara (NASDAQ:CERT) Shares Gap Down to $17.89
SVB Leerink Trims Certara (NASDAQ:CERT) Target Price to $26.00
Certara Announces Secondary Offering
Certara, Inc. (CERT) Q2 2022 Earnings Call Transcript
Certara Reports Second Quarter 2022 Financial Results
See More Headlines
Receive CERT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Certara and its competitors with MarketBeat's FREE daily newsletter.

CERT Company Calendar

Last Earnings
8/09/2022
Today
9/08/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Prepackaged software
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CERT
Fax
N/A
Employees
1,114
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$26.13
High Stock Price Forecast
$41.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+62.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
8 Analysts

Profitability

Net Income
$-13,270,000.00
Pretax Margin
0.95%

Debt

Sales & Book Value

Annual Sales
$286.10 million
Cash Flow
$0.29 per share
Book Value
$6.52 per share

Miscellaneous

Free Float
153,455,000
Market Cap
$2.62 billion
Optionable
Not Optionable
Beta
1.27

Key Executives

  • Dr. William F. Feehery Ph.D.Dr. William F. Feehery Ph.D. (Age 51)
    CEO & Director
    Comp: $1.24M
  • Mr. M. Andrew Schemick (Age 48)
    Chief Financial Officer
    Comp: $568.7k
  • Mr. Leif E. Pedersen (Age 58)
    Pres of Software
    Comp: $434.11k
  • Dr. Robert P. Aspbury Ph.D. (Age 50)
    Pres of Simcyp Division
    Comp: $541.23k
  • Mr. Andrew Schemick
    Chief Financial Officer
  • Prof. Amin Rostami PharmD
    Ph.D., FCP, Chief Scientific Officer
  • Mr. Richard M. TraynorMr. Richard M. Traynor (Age 50)
    Sr. VP, Gen. Counsel & Sec.
  • Ms. Jieun W. ChoeMs. Jieun W. Choe (Age 47)
    Chief Strategy & Marketing Officer
  • Mr. Ron DiSantis
    Sr. VP of Corp. Devel.
  • Ms. Nicolette D. Sherman (Age 52)
    Chief HR Officer













CERT Stock - Frequently Asked Questions

Should I buy or sell Certara stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Certara in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CERT shares.
View CERT analyst ratings
or view top-rated stocks.

What is Certara's stock price forecast for 2022?

8 brokers have issued 12 month price objectives for Certara's stock. Their CERT share price forecasts range from $20.00 to $41.00. On average, they predict the company's share price to reach $26.13 in the next twelve months. This suggests a possible upside of 59.4% from the stock's current price.
View analysts price targets for CERT
or view top-rated stocks among Wall Street analysts.

How have CERT shares performed in 2022?

Certara's stock was trading at $28.42 at the beginning of 2022. Since then, CERT stock has decreased by 42.3% and is now trading at $16.39.
View the best growth stocks for 2022 here
.

When is Certara's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our CERT earnings forecast
.

How were Certara's earnings last quarter?

Certara, Inc. (NASDAQ:CERT) posted its earnings results on Tuesday, August, 9th. The company reported $0.09 earnings per share for the quarter, missing analysts' consensus estimates of $0.11 by $0.02. The firm had revenue of $82 million for the quarter, compared to the consensus estimate of $85.46 million. Certara had a negative net margin of 3.14% and a positive trailing twelve-month return on equity of 4.26%. Certara's quarterly revenue was up 17.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.03 EPS.

What guidance has Certara issued on next quarter's earnings?

Certara issued an update on its FY 2022 earnings guidance on Tuesday, September, 6th. The company provided earnings per share guidance of $0.43-$0.48 for the period, compared to the consensus estimate of $0.50. The company issued revenue guidance of $325.00 million-$335.00 million, compared to the consensus revenue estimate of $355.09 million.

When did Certara IPO?

(CERT) raised $500 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 24,400,000 shares at a price of $19.00-$22.00 per share. Jefferies, Morgan Stanley, BofA Securities, Credit Suisse, Barclays and William Blair acted as the underwriters for the IPO.

What is Certara's stock symbol?

Certara trades on the NASDAQ under the ticker symbol "CERT."

Who are Certara's major shareholders?

Certara's stock is owned by many different institutional and retail investors. Top institutional investors include EQT Fund Management S.a r.l. (22.50%), Baillie Gifford & Co. (7.00%), William Blair Investment Management LLC (3.36%), Riverbridge Partners LLC (2.83%), JPMorgan Chase & Co. (2.54%) and Riverbridge Partners LLC (2.53%). Insiders that own company stock include Avatar Parent LP Eqt, Craig R Rayner, James E Cashman III, Jieun W Choe, Justin Edge, Mason P Slaine, Michael Andrew Schemick, Patrick F Smith, Richard M Traynor, Robert Aspbury, Stephen M Mclean and William F Feehery.
View institutional ownership trends
.

How do I buy shares of Certara?

Shares of CERT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Certara's stock price today?

One share of CERT stock can currently be purchased for approximately $16.39.

How much money does Certara make?

Certara (NASDAQ:CERT) has a market capitalization of $2.62 billion and generates $286.10 million in revenue each year. The company earns $-13,270,000.00 in net income (profit) each year or ($0.06) on an earnings per share basis.

How many employees does Certara have?

The company employs 1,114 workers across the globe.

How can I contact Certara?

Certara's mailing address is 100 OVERLOOK CENTER SUITE 101, PRINCETON NJ, 08540. The official website for the company is www.certara.com. The company can be reached via phone at 609-716-7900 or via email at ir@certara.com.

This page (NASDAQ:CERT) was last updated on 9/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.